Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules

NCT00848029 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT00848029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00848029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2008
Completion date
June 30, 2009
Enrollment
240 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pre-pandemic influenza vaccine